This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A recently unveiled cardiovasculardisease risk calculator that measures a patient's risk for heartattack and stroke is better calibrated and more precise than its previous version, but if current treatment guidelines for cholesterol and blood pressure therapy remain unchanged, the new calculator may have unintended consequences, according to research (..)
Researchers from the Johns Hopkins Bloomberg School of Public Health have developed a single universal risk prediction model for cardiovasculardisease that, in initial tests, works well for patients who already have cardiovasculardisease as well as patients who do not but who may be at risk for developing it.
Over the past 15 years, researchers have identified hundreds of regions in the human genome associated with heartattack risk. However, researchers lack efficient ways to explore how these genetic variants are molecularly connected to cardiovasculardisease, limiting efforts to develop therapeutics.
Researchers have identified a new target to treat atherosclerosis, a condition where plaque clogs arteries and causes major cardiac issues, including stroke and heartattack.
Researchers have discovered a better way of identifying those at high risk of potential heartattacks and strokes and other major cardiovasculardisease (CVD) events.
Researchers at Karolinska Institutet have identified a new potential risk marker for cardiovasculardisease in women. A new study shows an association between low levels of an anti-inflammatory antibody and the risk of heartattack and coronary heartdisease.
Researchers have identified a new pathway that contributes to cardiovasculardisease associated with high levels of niacin, a common B vitamin previously recommended to lower cholesterol. The team discovered a link between 4PY, a breakdown product from excess niacin, and heartdisease.
milla1cf Thu, 06/20/2024 - 19:40 June 20, 2024 — A programing algorithm, being tested by HonorHealth Research Institute for those patients with new or recently installed pacemakers, is designed so the device not only provides a steady heartbeat, but also controls high blood pressure. You just turn it on, and it works,” Dr.
Researchers have identified a new potential risk marker for cardiovasculardisease in women. A new study shows an association between low levels of an anti-inflammatory antibody and the risk of heartattack and coronary heartdisease.
The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardial infarction (STEMI), the most severe form of a heartattack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), 24), being held April 6-8 in Atltanta, GA.
A projected rise in heartdisease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 population could be affected by cardiovasculardisease within the next 30 years, according to two new science reports. and Susan F. to 61% of the U.S.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. Coronary inflammation is a crucial piece of the puzzle in predicting heartattack risk.
Recent guidelines have restricted aspirin use in the primary prevention of cardiovasculardisease. The American Heart Association (AHA)/American College of Cardiology (ACC) guidelines restricted aspirin to patients under 70, and more recently, the United States Preventive Services Task Force restricted aspirin use to patients under 60.
milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heartattack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.
When it comes to cardiovasculardisease, two of the biggest risk factors we must consider are: ApoB concentration - A measure of the number of circulating lipid particles. The greater the number of particles the artery wall is exposed to over time, the higher the risk of atherosclerosis and a heartattack 2.
“These patients often can’t control their blood pressure--placing them at significantly higher risk of heartattack, stroke and kidney failure.” The device delivers ultrasound energy through the arteries of the kidneys to deaden surrounding nerves that are overactive in many people with hypertension. Christine Albert, MD, MPH.
BackgroundThe United States uses the National Health Interview Survey (NHIS), Behavioral Risk Factor Surveillance System (BRFSS), and National Health and Nutrition Examination Survey to monitor disease trends and inform clinical care/prevention research. These 3 surveys share similar national estimates. 3.9]; NHIS: 3.0% [95% CI, 2.7,
Exercise prevents and reverses cardiovasculardisease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovasculardisease (CVD) prevention and reversal. A maximal exercise test (i.e.,
2, 2024 — Eko Health recently announced a new independent study from researchers at Imperial College London (Imperial) that demonstrated how AI can identify patients with significantly higher risk of experiencing major adverse cardiac events (MACE), including heartattacks and heart failure.
High levels of triglycerides and the lipid particles on which they are carried in the blood can contribute to the formation of “plaques” in the arteries that impede blood flow and can lead to heartattacks and strokes. A total of 229 patients (average age 55 years, 78% men and 90% White) were enrolled in the trial in eight countries.
In 2023, Gujarat grappled with a cardiac crisis, as reported by the Emergency Management and Research Institute (EMRI) 108, with a staggering 72,573 cases. Kamal Sharma, an interventional cardiologist based in the city, sheds light on the prevailing notion that cardiovasculardisease is higher in major urban centers like Ahmedabad and Surat.
Sleep deprivation also has some dire consequences for the cardiovascular system. This was one of my main research interests in graduate school when I was involved in projects related to the effects of sleep deprivation on blood vessel function (endothelial function)—a major risk factor for developing cardiovasculardisease.
Statins are a mainstay of heartdisease prevention, yet experts estimate that less than half of patients who are eligible to receive the drugs are currently taking them. Nissen, MD , chief academic officer in the Heart, Vascular, and Thoracic Institute at Cleveland Clinic and the study’s lead author.
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovasculardisease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heartdisease, said Matthew J.
A therapy that has been proven repeatedly to reduce the probability of heartattacks and strokes in multiple double-blind randomised controlled studies 1. We now have more than an additional decade of research on what the impact of statin therapy and aggressive cholesterol-lowering might have on cognitive function.
An analysis of data in the UK Biobank has found that COVID-19 infection may increase the risk of heartattack, stroke and death from any cause for up to three years for people with and without cardiovasculardisease, according to new research.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
People with type 2 diabetes had significantly fewer heartattacks, strokes, heart failures, and deaths from cardiovasculardisease when their blood pressure was lower than the current standard goal, a UT Southwestern Medical Center researcher and his colleagues found.
Clinicians currently use two separate risk models to assess patients’ chances of having heartattacks , strokes , and other major cardiovascular events. The study’s first author was Yejin Mok , PhD, MPH, a research associate who is also in the Bloomberg School’s Department of Epidemiology.
mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovasculardisease. mg)has potential to directly reduce inflammation, which plays a substantial role in the formation and progression of atherosclerotic plaque leading to heartdisease, said Matthew J.
Imagine a future where a silent, undetected heart condition is caught before it turns into a life-threatening event a future where artificial intelligence (AI) -powered insights alert clinicians to warning signs long before symptoms appear. Cardiovasculardisease (CVD) remains the leading cause of death in the U.S.
Kenneth Chan, MBBS, Academic Clinical Research Fellow in the Division of Cardiovascular Medicine at Oxford University Hospitals (UK) will receive the 2024 SCCT Clinical Trials and Registries Award (CTRA) at the opening session of the Society’s 19th Annual Scientific Meeting (SCCT2024) on Friday, July 19 in Washington, DC.
Some research suggests that moderate drinkers may have a lower risk of heartdisease compared to those who abstain or engage in heavy drinking. Drinking too much alcohol can lead to high blood pressure, a major risk factor for heartdisease.
They will also selectively support clinical research involving the CaRi-Heart technology for coronary inflammation diagnostics and LODOCO 0.5 Caristo shares Agepha Pharma’s passion for fighting coronary inflammation, which is one of the primary drivers of heartattack risks,” said Frank Cheng , CEO of Caristo Diagnostics.
The Schottenstein Prize is among the largest monetary prizes in the United States dedicated to cardiovascularresearch. Gerald and Myra Dorros Chair in CardiovascularDisease at Albert Einstein and serves as director of the Einstein Wilf Family CardiovascularResearch Institute.“Dr.
For individuals with cardiovasculardiseases, the limit is even lower at 1,500 mg/day, according to guideline recommendations from the ACC and the American Heart Association. Yet, adhering to a low sodium diet remains challenging even for individuals with cardiovasculardisease who have a strong incentive to adhere.”
Cleerly is dedicated to creating a new standard of care for heartdisease by using FDA-cleared solutions powered by artificial intelligence. We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working towards our goal of eliminating heartattacks.” “We
Eighty percent of heartattacks and strokes are preventable. partially because its key risk factor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heartattack or stroke. Yet, CVD remains the leading cause of death in the U.S.,
Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovasculardisease affecting up to 20% of the world’s population.
While the spotlight in 2023 shone on developments around Generative Artificial Intelligence (AI), away from the limelight a quiet revolution in AI was taking place, which promises to transform the way we diagnose, manage, and treat cardiovasculardiseases, the world’s leading cause of death.
Within the complex umbrella of cardiovasculardisease, CAD is a type of heartdisease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart.
In a recent study, researchers from Japan tested a novel approach that involves injecting ‘cardiac spheroids,’ cultured from human stem cells, directly into damaged ventricles. Cardiovasculardiseases are still among the top causes of death worldwide, and especially prevalent in developed countries.
Our findings show that interventions based on techniques from behavioral economics can achieve and sustain increased levels of physical activity in a population with risk factors for cardiovasculardisease and could be another tool to help reduce cardiovascular risk.”
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
98 
Let's personalize your content